Table 3.

Mean ± SE change from baseline to week 24 for applicable endpoints in rule-positive and rule-negative patients in MOBILITY, MONARCH, TARGET, and ASCERTAIN

	MOBILITY						MONARCH
	Sarilumab		Placebo		Sarilumab − placebo		Sarilumab		Adalimumab
	Rule-positive	Rule-negative	Rule-positive	Rule-negative	Rule-positive	Rule-negative	Rule-positive	Rule-negative	Rule-positive	Rule-negative
CDAI	− 30.0 ± 1.1	− 25.9 ± 1.0	− 20.0 ± 1.4	− 19.4 ± 1.3	− 10.0	− 6.4	− 32.8 ± 1.7	− 27.4 ± 1.2	− 24.1 ± 1.7	− 27.2 ± 1.3
DAS28-CRP	− 3.4 ± 0.1	− 2.6 ± 0.1	− 1.7 ± 0.1	− 1.4 ± 0.1	− 1.7	− 1.1	− 3.5 ± 0.2	− 2.6 ± 0.1	− 2.2 ± 0.2	− 2.0 ± 0.1
DAS28-ESR	N/A	N/A	N/A	N/A	N/A	N/A	− 3.7 ± 0.2	− 3.1 ± 0.1	− 2.1 ± 0.2	− 2.4 ± 0.1
HAQ-DI	N/A	N/A	N/A	N/A	N/A	N/A	− 0.9 ± 0.1	− 0.5 ± 0.1	− 0.5 ± 0.1	− 0.4 ± 0.1

	TARGET						ASCERTAIN
	Sarilumab		Placebo		Sarilumab − placebo		Sarilumab		Tocilizumab
	Rule-positive	Rule-negative	Rule-positive	Rule-negative	Rule-positive	Rule-negative	Rule-positive	Rule-negative	Rule-positive	Rule-negative
CDAI	− 30.8 ± 1.8	− 30.0 ± 1.7	− 23.7 ± 2.3	− 24.0 ± 1.5	− 7.1	− 6.0	N/A	N/A	N/A	N/A
DAS28-CRP	− 3.3 ± 0.2	− 3.1 ± 0.2	− 2.0 ± 0.2	− 1.9 ± 0.2	− 1.3	− 1.1	− 3.8 ± 0.3	− 2.4 ± 0.2	− 3.1 ± 0.2	− 2.4 ± 0.2
DAS28-ESR	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HAQ-DI	− 0.7 ± 0.1	− 0.7 ± 0.1	− 0.4 ± 0.1	− 0.6 ± 0.1	− 0.3	− 0.1	− 0.7 ± 0.2	− 0.5 ± 0.1	− 0.7 ± 0.1	− 0.5 ± 0.1

The patient stratification rule was the combined presence of anti-CCP and CRP > 12.3 mg/l

CDAI Clinical Disease Activity Index, DAS28-CRP 28-joint Disease Activity Score using C-reactive protein, DAS28-ESR DAS28 using erythrocyte sedimentation rate, HAQ-DI Health Assessment Questionnaire-Disability Index, N/A not applicable